Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) Net Income towards Common Stockholders (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Net Income towards Common Stockholders for 4 consecutive years, with -$35.9 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 183.72% to -$35.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$82.1 million through Dec 2025, down 69.59% year-over-year, with the annual reading at -$82.1 million for FY2025, 65.02% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$35.9 million at LENZ Therapeutics, down from -$16.7 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$10.2 million in Q3 2024, with the low at -$35.9 million in Q4 2025.
  • Average Net Income towards Common Stockholders over 4 years is -$18.8 million, with a median of -$15.3 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders soared 51.4% in 2023, then plummeted 183.72% in 2025.
  • Over 4 years, Net Income towards Common Stockholders stood at -$26.8 million in 2022, then increased by 29.8% to -$18.8 million in 2023, then skyrocketed by 32.63% to -$12.7 million in 2024, then tumbled by 183.72% to -$35.9 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$35.9 million, -$16.7 million, and -$14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.